Company Overview - Huajian Medical Holdings Limited was established on January 15, 2016, under the laws of the Cayman Islands, primarily engaged in investment holding [3] - The company operates three subsidiaries in Hong Kong: Weida Medical Limited, China Inspection International Limited, and Avid (China) Limited, with additional subsidiaries or branches in major cities across mainland China [3] - Huajian Medical focuses on research, production, and sales of in vitro diagnostic medical instruments and consumables, employing over 700 staff [3] Financial Performance - As of December 31, 2024, Huajian Medical reported total revenue of 3.162 billion yuan, a year-on-year increase of 2.4% [2] - The net profit attributable to shareholders was 260 million yuan, reflecting a year-on-year growth of 9.35% [2] - The gross profit margin stood at 23.75%, while the debt-to-asset ratio was 31.91% [2] Stock Performance - As of July 15, the stock price of Huajian Medical closed at 2.28 HKD per share, marking a 12.87% increase with a trading volume of 445,000 shares and a turnover of 977,600 HKD [1] - Over the past month, the stock has experienced a cumulative decline of 10.62%, while year-to-date, it has risen by 12.22%, underperforming the Hang Seng Index, which has increased by 20.65% [2] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -3.18 times, with a median of 1.17 times [3] - Huajian Medical's P/E ratio is 11.65 times, ranking 21st in the industry [3] - Comparatively, other companies in the sector have varying P/E ratios, with Giant Medical Holdings at 0.28 times, Jingjiu Medical at 0.38 times, and others ranging up to 5.4 times [3] Important Events - A significant event is anticipated on July 14, 2025, where the company expects a decrease in mid-year performance, projecting a profit attributable to shareholders of approximately 33 million RMB, a decline of 73.6% year-on-year [4]
华检医疗（01931.HK）7月15日收盘上涨12.87%，成交97.76万港元